171 related articles for article (PubMed ID: 22580817)
21. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer.
Hyodo I; Doi T; Endo H; Hosokawa Y; Nishikawa Y; Tanimizu M; Jinno K; Kotani Y
Eur J Cancer; 1998 Dec; 34(13):2041-5. PubMed ID: 10070308
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.
Cetin B; Kaplan MA; Berk V; Ozturk SC; Benekli M; Isıkdogan A; Ozkan M; Coskun U; Buyukberber S
Asian Pac J Cancer Prev; 2012; 13(3):1059-63. PubMed ID: 22631638
[TBL] [Abstract][Full Text] [Related]
23. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2014 Sep; 13(3):135-44. PubMed ID: 24768040
[TBL] [Abstract][Full Text] [Related]
24. Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer.
Kohli M; Kaushal V; Spencer HJ; Mehta P
Urology; 2003 Apr; 61(4):765-9. PubMed ID: 12670562
[TBL] [Abstract][Full Text] [Related]
25. Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer.
Yaman E; Uner A; Er O; Coskun U; Buyukberber S; Dikilitas M; Polat M; Yamac D; Kaya AO; Yildiz R; Ozturk B; Benekli M
Med Oncol; 2007; 24(4):431-5. PubMed ID: 17917094
[TBL] [Abstract][Full Text] [Related]
26. Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial.
Saltarella I; Morabito F; Giuliani N; Terragna C; Omedè P; Palumbo A; Bringhen S; De Paoli L; Martino E; Larocca A; Offidani M; Patriarca F; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Grasso M; Leonardi G; Rizzo M; Falcone AP; Gottardi D; Montefusco V; Musto P; Petrucci MT; Dammacco F; Boccadoro M; Vacca A; Ria R
J Hematol Oncol; 2019 Jan; 12(1):4. PubMed ID: 30626425
[TBL] [Abstract][Full Text] [Related]
27. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S16-20. PubMed ID: 18361802
[TBL] [Abstract][Full Text] [Related]
28. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma.
Sezer O; Jakob C; Eucker J; Niemöller K; Gatz F; Wernecke K; Possinger K
Eur J Haematol; 2001 Feb; 66(2):83-8. PubMed ID: 11168514
[TBL] [Abstract][Full Text] [Related]
29. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Rittweger K; Gilberg F; Saltz L
Br J Cancer; 2011 Jun; 105(1):58-64. PubMed ID: 21673685
[TBL] [Abstract][Full Text] [Related]
30. Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients.
Loven D; Be'ery E; Yerushalmi R; Koren C; Sulkes A; Lavi I; Shaked Y; Fenig E
Acta Oncol; 2008; 47(1):104-9. PubMed ID: 17851858
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of serum angiogenic activity in colorectal cancer patients.
Gonzalez FJ; Quesada AR; Sevilla I; Baca JJ; Medina MA; Amores J; Diaz JM; Rius-Diaz F; Marques E; Alba E
J Cell Mol Med; 2007; 11(1):120-8. PubMed ID: 17367506
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
Waddell T; Gollins S; Soe W; Valle J; Allen J; Bentley D; Morris J; Lloyd A; Swindell R; Taylor MB; Saunders MP
Cancer Chemother Pharmacol; 2011 May; 67(5):1111-7. PubMed ID: 20676676
[TBL] [Abstract][Full Text] [Related]
33. New oxaliplatin-based combinations in the treatment of colorectal cancer.
Cassidy J; Hochster H
Colorectal Dis; 2003 Nov; 5 Suppl 3():1-9. PubMed ID: 23573555
[TBL] [Abstract][Full Text] [Related]
34. Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer.
Cubillo A; Álvarez-Gallego R; Muñoz M; Pond G; Perea S; Sánchez G; Martin M; Rodríguez-Pascual J; Garralda E; Vega E; de Vicente E; Quijano Y; Muñoz C; Ugidos L; Toledo RA; Hidalgo M
Am J Clin Oncol; 2019 Jan; 42(1):56-59. PubMed ID: 29975196
[TBL] [Abstract][Full Text] [Related]
35. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
Díaz-Rubio E; Gómez-España A; Massutí B; Sastre J; Abad A; Valladares M; Rivera F; Safont MJ; Martínez de Prado P; Gallén M; González E; Marcuello E; Benavides M; Fernández-Martos C; Losa F; Escudero P; Arrivi A; Cervantes A; Dueñas R; López-Ladrón A; Lacasta A; Llanos M; Tabernero JM; Antón A; Aranda E;
Oncologist; 2012; 17(1):15-25. PubMed ID: 22234633
[TBL] [Abstract][Full Text] [Related]
36. Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies.
Mammoliti S; Andretta V; Bennicelli E; Caprioni F; Comandini D; Fornarini G; Guglielmi A; Pessino A; Sciallero S; Sobrero AF; Mazzola G; Lambiase A; Bordignon C
Ann Oncol; 2011 Apr; 22(4):973-978. PubMed ID: 20855468
[TBL] [Abstract][Full Text] [Related]
37. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
[TBL] [Abstract][Full Text] [Related]
38. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
[TBL] [Abstract][Full Text] [Related]
39. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.
Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Xekalou A; Alegakis A; Boula A; Stathopoulos EN; Alexandrakis MG
Cytokine; 2011 Dec; 56(3):616-20. PubMed ID: 21940178
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
Tol J; Koopman M; Cats A; Rodenburg CJ; Creemers GJ; Schrama JG; Erdkamp FL; Vos AH; van Groeningen CJ; Sinnige HA; Richel DJ; Voest EE; Dijkstra JR; Vink-Börger ME; Antonini NF; Mol L; van Krieken JH; Dalesio O; Punt CJ
N Engl J Med; 2009 Feb; 360(6):563-72. PubMed ID: 19196673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
